Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients withAKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

MLA

Ingrid A. Mayer, et al. “Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients WithAKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer.” Clinical Cancer Research, vol. 26, Aug. 2020, pp. 3947–57. EBSCOhost, https://doi.org/10.1158/1078-0432.ccr-19-3953.

APA

Ingrid A. Mayer, Sarat Chandarlapaty, Gaia Schiavon, Vicky Rowlands, Martin Pass, Elza C. de Bruin, Helen Ambrose, Claire Corcoran, Andrew Foxley, Kenji Tamura, David M. Hyman, Maurizio Scaltriti, Eva Ciruelos, Jack Ashton, José Baselga, Lillian M. Smyth, Joana Hauser, Justin P.O. Lindemann, Des D. Cashell, … Marie-Paule Sablin. (2020). Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients withAKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research, 26, 3947–3957. https://doi.org/10.1158/1078-0432.ccr-19-3953

Chicago

Ingrid A. Mayer, Sarat Chandarlapaty, Gaia Schiavon, Vicky Rowlands, Martin Pass, Elza C. de Bruin, Helen Ambrose, et al. 2020. “Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients WithAKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer.” Clinical Cancer Research 26 (August): 3947–57. doi:10.1158/1078-0432.ccr-19-3953.